2024 Cardiovascular Big Five Annual Report: Intense Competition in Key Segments, Giants Battle for Dominance

The Opening Chapter of the Cardiovascular Market

In the global health industry landscape, the cardiovascular device market is booming at an astonishing rate.2024 In , the global cardiovascular device market value soared to 728.3 Billion USD, year-on-year growth 7%，This figure is like a dazzling star, illuminating the development path of the medical industry. Among them, the interventional cardiology market takes the lead, occupying the largest share of the cardiovascular device market and becoming the undisputed dominant force.The structural heart disease market, on the other hand, has the highest GAGR Growth, demonstrating enormous development potential and limitless possibilities.

In this highly competitive track,2024 Annual Electrophysiology (PFA) and structural heart disease (valves) have become the hottest tracks,Attracting the attention of numerous enterprises and an influx of capital. In the electrophysiology field, Johnson & Johnson, with its deep technical expertise and extensive market presence, firmly holds the leading position; Boston Scientific relies on innovative PFA Technology, with a strong impact on the market, attempts to break the existing pattern; Medtronic,不甘示弱, demonstrates full “Gunpowder Flavor”, actively engaging in this fierce competition.

Especially PFA The level of competition in this field is so intense that it inevitably reminds people of the fierce battle over coronary artery stents years ago—truly a case of the first battle being the decisive one.

Boston Scientific Holds the World's First Commercialized PFA Product —FARAPULSE The system, like wielding a sharp blade, cuts through the thorns in the market.2024 Year 10 Month, Boston Scientific launched a new generation of catheters FARAWAVE NAV, further solidifying its leading position in this track, is undoubtedly PFA Track's “The King”。

Johnson & Johnson VARIPULSE The system is also not to be underestimated,2024 Year 2 Month and 11 Respectively obtained in the EU CE And the United States FDA 's approval, its influence in the global market is growing day by day. In China, the system has entered “Green Channel”, and is currently awaiting approval. Once approved, it is bound to create a stir in the Chinese market. According to electrophysiological data, Johnson & Johnson ranks first in the industry, which speaks volumes about its strength.

Medtronic also performed outstandingly, with its launch in the U.S. market as the first PFA Product —PulseSelect The system quickly gained market recognition.2024 Year 10 Month, another product launched by Medtronic PFA Product Sphere - 9 Obtain FDA Approved, becoming the world's first to provide patients with two PFA Companies with clinical technology pathways have rightfully become PFA Track's “Volume King”。

In the field of structural heart disease, Edwards, Medtronic, and Abbott rank TOP3, becoming the leader in the industry. In the valve sector, the peak confrontation between Edwards and Medtronic has attracted countless people's attention. Edwards Life business TAVR Undoubtedly, it is “Cash Cow”, bringing substantial profits to the company. Currently, Edwards is focusing on acceleratingTAVR Iteration and TMTT Pipeline Development: Future Expectations TMTT To create a second growth curve and further consolidate its leading position in the field of structural heart disease.2024 Year, Edwards Life Sciences with TAVR、TMTT And surgical valves, these three important growth engines, have become the absolute leader in the field of valve treatment.

Medtronic in TAVR Although the market is not as strong as Edwards, it has been actively seeking new breakthroughs. Against this background,Harmony TPV Emerging out of nowhere.2025 Year 1 Month, Medtronic Harmony Transcatheter Pulmonary Valve (TPV) System obtained CE Symbol, becoming the world's first self-expanding pulmonary valve. The emergence of this product has brought new opportunities for Medtronic in the field of structural heart disease and also brought new hope to patients.

Then, in 2024 In this year full of challenges and opportunities, what kind of spectacular annual drama did the cardiovascular giants—Medtronic, Abbott, Boston Scientific, Johnson & Johnson Medical, and Edwards Lifesciences—stage? Let’s dive into their annual reports to uncover the mysteries within.

Revenue Secrets of the Big Five

(1) Overall Ranking and Growth Rate

In 2024 In this fierce market competition of the year, the ranking of the global top five cardiovascular giants remains stable.

• Medtronic, with its deep heritage and extensive market presence, continues to lead in cardiovascular business revenue, achieving an impressive 118.31 Million Swiss francs, demonstrating strong capabilities and market influence.

• Abbott followed closely, with 112.19 Medtronic ranked second with billions of dollars in revenue, and its diversified development strategy in the cardiovascular field has achieved remarkable results.

• Boston Scientific has achieved revenue growth through innovative products and market strategies. 107.55 billion dollars, ranking third, with a very strong growth momentum.

• Johnson & Johnson Medical ( 77.05 Ranked fourth in revenue with billions of dollars, its outstanding performance in fields such as electrophysiology has provided strong support for its growth.

• Edwards Lifesciences 54.4 Ranked fifth with billions of dollars in revenue, its focus on the development of cardiovascular business has gradually highlighted its advantages in this field.

In terms of growth rate,Boston Scientific 22% The astonishing growth rate ranked first, making it the fastest-growing company among the top five..The rapid growth of its cardiovascular business is mainly due to FARAPULSE™The rapid global popularity of the pulsed field ablation system has not only met market demands but also brought significant commercial value to the company.The growth rate of Johnson & Johnson Medical is also impressive, reaching 21.4%, second only to Boston Scientific. The strong performance of its electrophysiology business, as well asAbiomed And Shockwave The successful acquisitions of companies have injected strong momentum into their revenue growth.Abbott's growth rate is 9.6%, Through continuous launch of new products and expansion of market share, it has achieved significant growth in fields such as structural heart disease. The growth rate of Edwards Lifesciences is 8.9%, focusing on the development of cardiovascular business, making it in TAVR ...and other core businesses maintained steady growth. In contrast, Medtronic's growth rate was relatively moderate, at... 2.7%，Despite this, its massive revenue scale still allows it to hold a significant position in the cardiovascular field.

(II) Analysis of Business Segments of Major Players

Medtronic's cardiovascular business is like a vast and complex commercial empire, with its cardiac rhythm and heart failure division being the largest segment of its cardiovascular operations.2024 The year has shown strong growth momentum. Revenue reached 59.95 Billion USD, year-on-year growth 3.7%，This achievement is mainly due to the high single-digit growth in the fields of defibrillation solutions and cardiac pacing therapy. In terms of defibrillation solutions, Medtronic has continuously invested in research and development, launching a series of more efficient and convenient products to meet the needs of different patients. Its cardiac pacing therapy products have also made breakthroughs in technology, improving the accuracy and effectiveness of treatment, and gaining market recognition.

Revenue from structural heart disease and aortic business is 33.58 billion dollars, although it has only slightly - 0.1% Changes, but the structural heart business achieved high single-digit growth. Medtronic's innovative achievements in the field of structural heart disease have been remarkable, with several products launched receiving positive market feedback. Revenue from coronary and peripheral vascular businesses 24.78 USD billion, year-on-year growth 4.3%In the field of coronary arteries, Medtronic's guiding catheters and balloons, with their superior performance, have secured a place in the market; in the field of peripheral vascular health, its products continue to improve, providing patients with better treatment options.

Abbott's cardiovascular business has shown a diversified growth trend. Among the cardiovascular segments, cardiovascular (coronary intervention, peripheral vascular intervention), as the largest sub-module, generated revenue. 28.37 USD billion, year-on-year growth 5.8%In the field of coronary intervention, Abbott continuously optimizes product performance to improve the success rate and safety of surgeries; in the field of peripheral vascular intervention, its products also keep innovating to meet the treatment needs of different patients.

Rhythm Management Revenue 23.9 Billion USD, year-on-year growth 6%, Abbott has improved the accuracy and stability of its rhythm management products through continuous technological advancements. Electrophysiology revenue 24.67 Billion USD, year-on-year growth 12.3%, Thanks to its continuous innovation and market expansion in the electrophysiology field, multiple products launched have gained widespread application in the market. Revenue from structural heart disease 22.46 Billion USD, year-on-year growth 15.8%`, with the largest increase. This is mainly due to` TriClip™Tricuspid valve repair device,Amplatzer™Left Atrial Appendage Occluder,Volt™ PFA The launch of key products such as devices. The innovative technology and excellent performance of these products have given Abbott a competitive advantage in the field of structural heart disease. Heart failure revenue 12.79 Billion USD, year-on-year growth 10.2%Abbott's technological breakthroughs and product innovations in the field of heart failure treatment have provided patients with more effective treatment options.

Boston Scientific's cardiovascular business growth is mainly attributed to its great success in the electrophysiology field. Cardiology revenue 83.44 Billion USD, year-on-year growth 32%, including revenue from interventional cardiology treatments 26.45 USD billion, year-on-year growth 11%。WATCHMAN™Annual Sales of Left Atrial Appendage Closure Devices 15.16 Billion USD, Year-on-Year Growth 19.2%, the product has gained high recognition in the market due to its advanced technology and good safety. Heart rhythm management increased year by year. 2.8%`, Revenue` 22.79 Billion dollars, thanks to LUX-Dx™ II + The strong demand for implantable cardiac monitoring devices has provided a more precise means of monitoring for rhythm management.

Electrophysiology Growth Shines Brightest, with Full-Year Sales 19.04 billion dollars, a sharp increase year-on-year 139.5%, which is mainly due to FARAPULSE™The Rapid Popularization of the Pulsed Field Ablation System. The innovative technology and highly efficient treatment outcomes of this system have attracted significant attention from many doctors and patients, quickly securing its position in the market. Peripheral intervention revenue 24.1 Billion USD, year-on-year growth 14.2%, Boston Scientific's products in the peripheral intervention field continue to upgrade, providing patients with a better treatment experience.

The growth of Johnson & Johnson Medical's cardiovascular business is mainly driven by electrophysiology. Electrophysiology revenue 52.67 USD billion, a year-on-year increase of 12.7%, with the growth of global surgical volume and the launch of new products (QDOT OCTARAY、Carto ELEVATE、Carto SoundFAM) and commercial promotion, Johnson & Johnson's market share in the electrophysiology field continues to expand.Abiomed Revenue 14.96 Billion USD, year-on-year growth 14.5%, the heart pump manufacturer is Johnson & Johnson in 2022 Year 11 Acquired in the month of the acquisition, after which Johnson & Johnson fully integrated resources and promotedAbiomed The rapid development of the business.

Shockwave Revenue 5.64 Billion US dollars,2024 Year 5 Following its acquisition by Johnson & Johnson last month, the company now operates as a division of Johnson & Johnson's medical technology business. Its advanced technologies and products have injected new momentum into Johnson & Johnson's cardiovascular business. Revenue from other cardiovascular businesses 3.8 Billion USD, year-on-year growth 6.9%, although it accounts for a relatively small proportion, it also maintains a steady growth trend.

After spinning off its critical care business, Edwards Lifesciences has become a pure-play cardiovascular company. Transcatheter Aortic Valve Replacement (TAVR) as its core business, revenue 41.06 Billion USD, Year-over-Year Growth 5.8%, mainly due to SAPIEN 3 Ultra RESILIA The driving force behind growth. The outstanding performance and positive market reputation of this product have made it a significant revenue source for Edwards Lifesciences.

Transcatheter Mitral and Tricuspid Valve Therapies (TMTT) Revenue 3.52 USD billion, a year-on-year increase of 78.2%, growing rapidly. Edwards Lifesciences' continuous investment and innovation in this field have led to the launch of a series of advanced products and treatment solutions, meeting market demands. Revenue from surgical structural heart business 9.81 USD billion, year-on-year growth 5.2%, by RESILIA Driven by the widespread adoption and overall growth of the product. The high quality and broad application of the product provide strong support for the growth of the surgical structural heart business.

Global Technology Competition in Progress

(1) Electrophysiology:PFA Sanguosha

In the field of electrophysiology,2024 The year is undoubtedly PFA A year of remarkable technological achievements, with Johnson & Johnson, Medtronic, and Boston Scientific as the three major giants around PFA The unfolding competition is nothing short of a spectacular “Sanguosha”。

Medtronic, with its forward-looking strategic vision and strong R&D capabilities, in PFA Early layout in the field, fruitful harvest. Its PulseSelect The system is like a brilliant star, in 2023 Year 11 Month takes the lead in obtaining EU CE Certification, followed by 2023 Year 12 Successfully captured the U.S. market in a month FDA Approval,2024 Year 5 Month and 9 The product was successfully launched in Japan and China respectively this month. This series of achievements not only highlights Medtronic's PFA The leading position in technology has also laid a solid foundation for its expansion in the global market.2024 Year 10 In the same month, Medtronic followed up on its success with its second product PFA Product Sphere - 9 And its matching use Affera Mapping Ablation System Receives U.S. Approval FDA Approval of this groundbreaking advancement makes Medtronic the first company in the industry able to offer patients two PFA Companies with clinical technology pathways have significantly enhanced their competitiveness in the electrophysiology market.PulseSelect The system, with its advantage of being approved earlier, quickly gained a foothold in the market, winning a large number of users and good reputation for Medtronic; and Sphere - 9 Thanks to its unique technical design and innovative functions, it provides doctors and patients with more options and better treatment outcomes.

Boston Scientific is also in PFA The field has demonstrated strong capabilities and competitiveness. Its FARAPULSE System as the world's first commercialized PFA Product, in 2021 Year 1 Debut with a radiant moon, gaining the EU CE Certification, Activated PFA A New Era of Commercialization. Subsequently, in 2024 Year 1 Month,7 Month and 9 Month,FARAPULSE The system was once again successfully approved in the United States FDA, China NMPA And Japan PDMA The marketing authorization has been obtained, achieving a comprehensive layout in core markets worldwide. With the help of FARAPULSE The system's continued popularity worldwide has driven rapid growth in Boston Scientific's electrophysiology business revenue, becoming a strong driver for the company’s development.2024 Year 10 Month, Boston Scientific launched a new generation catheter with 3D mapping function FARAWAVE NAV Obtained in the United States FDA Registration certification, this innovative product, further enhances Boston Scientific's PFA Technical advantages and market competitiveness in the field.FARAPULSE The system has gained high recognition from doctors and patients with its advanced technology and excellent performance; and FARAWAVE NAV By introducing three-dimensional mapping capabilities, surgical procedures become more precise and efficient, offering patients a better treatment experience.

Johnson & Johnson in PFA Although its layout in the field started relatively late, it quickly gained prominence in the market by virtue of its strong technical capabilities and powerful market promotion abilities. VARIPULSE System in 2024 Year 1 Month,2 Month and 11 Respectively obtained in Japan in the month PDMA, EU CE And the United States FDA The approval has enabled rapid access in major global markets. The system can be integrated with Johnson & Johnson's already extensive and advanced performance Carto 3 The combination of the three-dimensional mapping system offers a unique advantage, which is expected to provide a boost. VARIPULSE The system has achieved accelerated growth in the market. Meanwhile, Johnson & Johnson is also actively promoting its ThermoCool SmartTouch SF Catheter and Omnypulse Progress of Catheter Development, IncludingThermoCool SmartTouch SF The catheter is “PFA + Radiofrequency” Dual-energy catheter,Omnypulse The catheter adopts an expandable basket design and integrates pressure monitoring with enhanced 3D mapping capabilities. The launch of these innovative products will further enrich Johnson & Johnson's product portfolio in the electrophysiology field and enhance its market competitiveness.VARIPULSE System and Carto 3 The combined use of the three-dimensional mapping system provides doctors with more comprehensive and accurate surgical information, which helps to improve the success rate and safety of the surgery. ThermoCool SmartTouch SF Catheter and Omnypulse The development of catheters demonstrates Johnson & Johnson's relentless efforts and outstanding capabilities in technological innovation.

(II) Structural Heart Disease: The Valve Leader and the Pursuers

In the field of structural heart disease, the valve market has always been the focus of competition among major enterprises. With its profound technical accumulation, extensive clinical experience, and broad market layout, Edwards Lifesciences has become the undisputed leader in this field.2024 Year 9 Last month, Edwards Lifesciences completed the sale of its critical care assets, a strategic decision that allows the company to focus more resources and efforts on its cardiovascular business, particularly in the field of structural heart disease. The proceeds from the sale were mainly used to accelerate this focus. TAVR Iteration and TMTT Pipeline development further solidifies its leading position in the valve market.

In TAVR Field, Edwards Lifesciences SAPIEN 3 Ultra RESILIA The product, with its superior performance and excellent market reputation, has become one of the company's core products, continuously driving the growth of the company's performance. The product adopts advanced technology and materials, offering higher safety and effectiveness, and is able to provide better treatment outcomes for patients. Meanwhile, Edwards Lifesciences also expanded through acquisitions. Affluent Medical The Epygon™Mitral Valve and JenaValve The Trilogy TAVR Systems and other pipelines, continuously enriching and perfecting their own product matrix, have formed “Repair + Replacement” A complete solution that meets the treatment needs of different patients.

Medtronic, as a key player in the structural heart disease field, has been striving to catch up with Edwards Life Sciences. TAVR The market, although Medtronic currently accounts for only 30%, accounting for a high proportion of 60% Edward Life Sciences, but Medtronic has not given up, instead actively seeking new breakthroughs.2025 Year 1 Month, Medtronic Harmony TPV Out of nowhere, this world's first self-expanding pulmonary valve has won new opportunities for Medtronic in the field of structural heart disease. Compared with competing products, Medtronic's Harmony TPV With significant advantages such as no need for balloon assistance, simpler operation, and lower surgical costs, these advantages make it有望成为后续 TPVR The mainstream design. Currently, Medtronic is actively promoting Harmony TPV The market promotion and clinical application of this product are believed to achieve excellent results in the market in the near future.

In addition to Medtronic, Abbott and Boston Scientific have also made active moves in the structural heart disease field. Abbott has continuously launched new products and technologies, such asTriClip™Tricuspid Valve Repair Device,Amplatzer™Left atrial appendage occluders and other devices are gradually gaining prominence in the field of structural heart disease. Boston Scientific, leveraging its technological advantages in cardiovascular interventions, continues to expand its business in the structural heart disease sector, launching a series of innovative products and solutions. However, Johnson & Johnson Medical currently has no presence in the structural heart disease space, and whether it will enter this field in the future remains to be seen. As the market continues to evolve and competition intensifies, the landscape of the structural heart disease field may change. Major companies are actively positioning themselves to secure a place in this promising market.

(III) Heart Failure and Pacemakers: The Duel of Two Titans and the Contest of Three Powers

In the fields of heart failure and pacemakers, there are respectively a two-power competition and a tripartite standoff.

In the field of artificial hearts, Abbott and Johnson & Johnson have become the two dominant players, engaging in fierce competition. Abbott's HeartMate 3 The artificial heart is the world's first third-generation centrifugal left ventricular assist device that uses magnetic levitation technology, and it is also one of only two globally approved devices for long-term support. With its advanced magnetic levitation technology, the product effectively reduces the risk of blood damage and thrombosis while enhancing the stability and reliability of the device, providing heart failure patients with a safer and more effective treatment option.HeartMate 3 The emergence fills a technical gap in the field of artificial hearts and leads the development trend of the industry.

Johnson & Johnson's Impella It is an invasive artificial heart assist device and is currently the only one that has received approval in the United States. FDA The approved interventional artificial heart product, also the earliest commercially available interventional artificial heart product, is called “The World's Smallest Artificial Heart”。Impella The uniqueness of this product lies in its compact size and convenient operation, allowing the device to be implanted in patients through minimally invasive intervention to provide timely cardiac support. The emergence of this product brings new hope to patients who are unable to undergo traditional heart surgery and opens up a new path for the development of artificial heart technology.

In the field of cardiac pacemakers, three major giants—Medtronic, Abbott, and Boston Scientific—are engaged in fierce competition. Medtronic, a long-established company in the cardiac pacemaker industry, boasts a rich product portfolio and deep technological expertise, with its products enjoying high recognition and reputation in the market. Abbott, through continuous innovation and technological upgrades, has made significant progress in the performance and functionality of its pacemakers, gradually securing a strong position in the market. Boston Scientific leverages its technological advantages in the cardiovascular intervention field, applying them to the research and production of pacemakers, and has introduced a series of innovative products, providing patients with more options. The competition among these three giants in the cardiac pacemaker sector not only drives constant technological advancement and innovation but also brings better treatment outcomes and improved quality of life for patients.

Opportunities and Challenges in the China Region

(1) Giant Layout Adjustment

In 2024 In recent years, global cardiovascular giants have accelerated their布局 in the Chinese market, actively adjusting their business strategies to adapt to the unique demands and development trends of the Chinese market.

Medtronic, as a leader in the cardiovascular field, has accelerated the integration of traditional cardiovascular platforms in China. By merging the original seven CV Operating Unit (OU) China Medtronic Consolidates Teams into Three to Optimize Resource Allocation, Improve Operational Efficiency, and Create Stronger Synergies. In the fields of Cardiac Rhythm Management, Cardiovascular Diagnostics, Cardiac Surgery, and Cardiac Ablation Solutions, the team will be led by Lin Song, Vice President of Cardiac Rhythm Management and Diagnostics Operations in China. He will oversee Medtronic’s cardiovascular product portfolio in China and promote deeper integration across various business units. In the areas of Structural Heart Disease, Aortic, and Peripheral Vascular Health, the team will be headed by Huang Fang, Vice President of the Greater China Structural Heart Business, who will continue to report globally. SH&A Senior Vice President and President Nina Goodheart Report, dedicated to promoting the development of related businesses in the Chinese market. The Coronary and Renal Denervation team in China is led by Jia Tao, the current Vice President of Coronary and Renal Artery Sympathetic Ablation Business in China, continuing to report to the global team. CRDN Senior Vice President and President Jason Weidman Report, focusing on business expansion in this field. This series of adjustments fully demonstrates Medtronic's high regard for the Chinese market, as well as its decisive decision-making and proactive actions in response to market changes.

Boston Scientific actively introduces innovative products in the field of peripheral interventions and accelerates their implementation in the Chinese market.2024 Year 3 Month, Boston Scientific successfully introduced RotaPro Rotational Atherectomy System, which adopts advanced rotational atherectomy technology, effectively removes plaque within blood vessels, providing a more efficient treatment method for peripheral vascular diseases.2024 Year 8 Month, Boston Scientific introduced again JETSTREAM The Atherectomy System, which can quickly and accurately remove plaques within blood vessels, enhancing the efficiency and safety of surgeries. The introduction of these two products not only enriches Boston Scientific's product line in the Chinese market but also offers more treatment options for Chinese patients. Meanwhile, Boston Scientific is actively advancing its localization strategy in China, strengthening cooperation with local suppliers and increasing the proportion of locally manufactured products to better meet the needs of the Chinese market.

Edwards Lifesciences, through the acquisition of China-based JenSym Medical, J-valve TF Overseas Rights, Accelerating Domestic Layout in China TAVR Market.J-valve TF It is an innovative transcatheter aortic valve replacement system with unique design and technical advantages, capable of providing patients with safer and more effective treatment options. This acquisition by Edwards Lifesciences enables it to quickly enter the Chinese market. TAVR Market, with the help of J-valve TF The technological and market advantages further expand its market share in China's structural heart disease field. At the same time, Edwards Lifesciences is actively conducting clinical trials and academic promotion activities in China, increasing doctors' and patients' awareness and recognition of its products, laying a solid foundation for its development in the Chinese market.

(II) Market Landscape under the Influence of Centralized Procurement

The implementation of the centralized procurement policy has been like a storm, profoundly changing the landscape of China's cardiovascular market. Cardiovascular consumables have long been under centralized procurement. “Deep Water Zone”, from pacemakers to guide wires, centralized procurement has covered the vast majority of categories.2020In the year, the dust settled on the coronary stent centralized procurement. Boston Scientific emerged as the biggest winner with its high-quality products and reasonable prices, while MicroPort, a China-produced brand, ranked first due to its strong foundation and technical strength in the domestic market. This outcome not only reflects the impact of the centralized procurement policy on market competition but also showcases the strength comparison between domestic and foreign enterprises in the cardiovascular consumables field.

In the electrophysiology field, foreign enterprises (Johnson & Johnson, Abbott, Medtronic, Boston Scientific) originally dominated the Chinese electrophysiology market, but with the deepening advancement of centralized procurement, their market share has decreased from 2020 Year's 90% Decrease to 2024 Year's 75%The implementation of the centralized procurement policy has reduced the price of electrophysiology products, increased market transparency and fairness, and provided opportunities for the development of domestically produced enterprises. Leading domestic companies such as MicroPort EP and HT Medical actively expand the electrophysiology market, increase R&D investment, and have launched a series of products with independent intellectual property rights. MicroPort EP's FlashPoint™ PFA The system has completed multi-center clinical trials and is expected 2025Approved in the year, this system adopts advanced pulsed electric field ablation technology, offering higher safety and effectiveness; SinuProne Medical'sPulseAblate™Entering the green approval channel, it is expected to be approved for marketing in the near future. The rise of these domestically produced enterprises has broken the monopoly of foreign-funded enterprises in the electrophysiology market, promoting market competition and development.

It is worth noting that,2024 The first centralized procurement in the valve field was carried out in China this year.2024 Year 6 Month 21 Recently, Guangzhou announced the "Guangzhou Medical Consumables Joint Procurement Document for Medical Institutions (Transcatheter Artificial Aortic Valve Replacement System, Rechargeable Implantable Deep Brain Stimulation Pulse Generator Kit, Flow Diverter Dense Mesh Stent)" and organized a joint procurement of medical consumables for medical institutions in Guangzhou. In this valve collection, only foreign companies Medtronic and Boston Scientific were selected, while multiple domestic companies such as Peijia Medical and Heartflow Medical made bids. Currently, the penetration rate of valves in China is still at a low level, but with the advancement of collection procurement, foreign companies will face greater challenges. The implementation of the collection procurement policy will reduce the price of valve products, improve product accessibility, and promote the development of the valve market. Domestic companies are expected to leverage the opportunities brought by collection procurement to further expand their market share and enhance their competitiveness. Meanwhile, foreign companies need to continuously optimize their products and services and improve cost-effectiveness to address the competition from domestic companies and the challenges posed by collection procurement policies.

Review 2024 In the year, the cardiovascular "Big Five" demonstrated their respective strengths and characteristics in terms of revenue, technological innovation, and market layout in China. Their competition and development have driven the entire cardiovascular market forward. In the future, with continuous technological advancements, the cardiovascular market is expected to witness more groundbreaking innovative products, further enhancing the treatment level of cardiovascular diseases. Meanwhile, the ongoing implementation of centralized procurement policies in China will also push companies to continuously optimize costs and improve product cost-effectiveness to adapt to market changes. We look forward to seeing how these giants will continue to lead the development of the cardiovascular field in the future. We also welcome our readers to share your views and expectations on the future development of the cardiovascular market in the comment section.